The availability of electronic health record (EHR)-based phenotypes allows for genome-wide association analyses in thousands of traits, and has great potential to identify novel genetic variants associated with clinical phenotypes. We can interpret the phenome-wide association study (PheWAS) result for a single genetic variant by observing its association across a landscape of phenotypes. Since PheWAS can test 1000s of binary phenotypes, and most of them have unbalanced (case:control = 1:10) or often extremely unbalanced (case:control = 1:600) case-control ratios, existing methods cannot provide an accurate and scalable way to test for associations. Here we propose a computationally fast score test-based method that estimates the distribution of the test statistic using the saddlepoint approximation. Our method is much faster than the state of the art Firth's test (~100 times). It can also adjust for covariates and control type I error rates even when the case-control ratio is extremely unbalanced. Through application to PheWAS data from the Michigan Genomics Initiative, we show that the proposed method can control type I error rates while replicating previously known association signals even for traits with a very small number of cases and a large number of controls.
Introduction
Over the last decade, genome wide association studies (GWASs) have proved instrumental to unravelling the genetic complexities of hundreds of diseases and traits and their associations with common genomic variations. To date, thousands of GWASs have identified more than 4000 significant loci to be associated with human diseases and traits. 1 However, since most GWASs investigate a single disease or trait, they cannot exploit the cross-phenotype associations or pleiotropy 2 where a single genetic variant can be associated with multiple phenotypes. Phenomewide association study (PheWAS) has been proposed as an alternative approach to take advantage of the pleiotropy phenomenon by studying the impact of genetic variations across a broad spectrum of human phenotypes or 'phenome'. It is a complementary approach to GWAS in the sense that while GWAS attempts to identify phenotype-to-genotype associations, PheWAS uses a genotype-tophenotype approach. The first PheWAS 3 was published as a proof-of-principle study, which demonstrated that the PheWAS strategy could be applied to successfully identify the expected genedisease associations. Additional studies [4] [5] [6] [7] [8] have shown that the PheWAS approach can further identify novel disease-SNP associations. 9 The PheWAS approach depends on the availability of detailed phenotypic information. Currently, most of the PheWASs are applied to clinical cohorts linked to electronic health records (EHR) and utilize the International Classification of Disease (ICD) billing codes to define clinical phenotypes. The ICD codes provide an intuitive ordering of the phenotypes based on clinical disease and trait classifications. Since the current genotyping and imputation technologies allow for genotyping tens of millions of variants at very low cost, 10 an extensive PheWAS can attempt to investigate the genotype-phenotype associations by performing genome-wide association analyses in thousands of traits. We can interpret the PheWAS result of a single genetic variant by observing its associations across the phenome. Such a PheWAS is exhaustive in nature and has great potential to identify novel variants associated with clinical diseases.
One of the main challenges of the PheWAS analysis is that most of the phenotypes are binary phenotypes with unbalanced (1:5) or often extremely unbalanced (1:600) case-control ratios (See Figure S1 ), since the data is collected in cohorts. Although standard asymptotic tests, such as the Wald, score and likelihood ratio tests, are relatively well calibrated and asymptotically equivalent 11 for common variants (minor allele frequency (MAF) > 0.05) in balanced case-control studies, they can inflate type I error for low frequency (0.01 < MAF ≤ 0.05) and rare variants (MAF ≤ 0.01) in unbalanced case-control studies. 12 Moreover, since the Wald and likelihood ratio tests need to calculate the likelihood or the maximum likelihood estimator under the full model, which is computationally expensive, they are not scalable for the amount of tests that PheWASs attempt. On the other hand, the score test is computationally efficient as it does not need to calculate the maximum likelihood under the full model. However, as mentioned before, it suffers from having highly inflated type I error rates in unbalanced studies. Ma is based on the score statistics and estimates the null distribution using the saddlepoint approximation [14] [15] [16] instead of the normal approximation 17 traditionally used in score tests. We further develop an improvement of our test (fastSPA) which renders the most computationally challenging steps to be dependant only on the number of carriers (subjects with at least one minor allele) rather than the sample size. This improved test can substantially reduce the computation time, especially for low frequency and rare variants where the number of carriers is very low compared to the sample size. The projected computation time of our method to test for 1500 phenotypes across 10 million SNPs is ~400 CPU-days (2000 cases, 18000 controls) which is more than a 100 times improvement over Firth's test. In addition, through the extensive simulation studies and analysis of the Michigan Genomics Initiative (MGI) data, we demonstrate that the proposed approach can control type I errors and is powerful enough to replicate known association signals.
Material and Methods

Logistic regression model and saddlepoint approximation method
We consider a case-control study with sample size n . For the th 
where  is a 1 k  vector of coefficients of the covariates, and  is the genotype log-odds ratio.
Under this model, we are interested in testing for the genetic association by testing the null 
and the mean and variance of S under 0
The traditional score test approximates the null distribution using a normal distribution which depends only on the mean and the variance of the score statistic. The p-value can be obtained by comparing the observed test statistic, s and     0 0, H N V S . Normal approximation works well near the mean of the distribution, but performs very poorly at the tails. The performance is especially poor when the underlying distribution is highly skewed, such as in unbalanced case-control outcomes 12 , since normal approximation cannot incorporate higher moments such as skewness. In addition, the convergence rate of normal approximation [18] [19] [20] 
and the estimate of the first and second order derivatives of K are
respectively. We note that , ' K K and ''
K are plug-in estimates in which we plug in ˆi  instead of i  . Then, according to the saddlepoint method (Barndorff-Nielson 15; 16 ), the distribution of S at s can be approximated by,
, t is the solution to the equation ) '(K t s  , and  is the distribution function of a standard normal distribution.
Implementation details and approaches to reduce the computation time
The saddlepoint approximation method involves finding the root of the saddlepoint equation
It is easy to verify that ' K is strictly increasing as ''( ) 0 K t  for all t     , and
Therefore a unique root exists, and we can use popular root-finding algorithms (Newton-Raphson, 22; and real-data applications we applied a combination of the Newton-Raphson and bisection method to solve the saddlepoint equations.
The most computationally demanding step in this saddlepoint approximation method is calculating the cumulant generating function and its derivatives. Here we propose several approaches to reduce the computational complexities associated with these calculations.
Faster calculation of the CGF using a partially normal approximation approach: The most computationally intensive step in the saddlepoint method is the calculation of the cumulant generating function K and its derivatives. In each step of the root-finding algorithm we need to calculate , ' K K and '' K , each of which needs ( ) O n computations. Using the fact that many elements of G are zeroes (i.e, homozygous major genotypes), we propose a fast computation method that speeds up the computation to ( ) O m , where m is the number of non-zero elements in G . Without loss of generality we assume that the first m subjects have at least one minor allele each and rests have homozygous major genotypes. We can then express S as
and l Z be the th l element of Z . Then we can further express 2 S as,
. Now, if we assume that the non-genetic covariates are relatively balanced in the sample, then the normal distribution should be a good approximation for the null distribution of each 2l S . Since 2 S is a weighted sum of the 2l S s, we can also approximate the null 8 distribution of 2 S using a normal distribution with mean and the variance under 0 H given by
Then, the CGF of 2 S can be approximated by,
In order to calculate the first two terms at the right hand side of ( 
Alternatively, we can adaptively select the threshold using the error bound of the normal approximation given by the Berry-Esseen theorem. Suppose we are interested in controlling the type I error rate at level  . Let ( ) n F x be the true distribution function of the standardized score test statistic 0 ( / ) H S V S . Then, according to Berry-Esseen theorem [18] [19] [20] , the maximum error bound in
As of now, the best known estimate for C is 0.56 , given by Shevtsova. 25 
Numerical Simulations
To evaluate the computation times, type I error rates and power of the proposed method, we carried out extensive simulation studies. We considered three different case-control ratios: balanced with 10000 cases and 10000 controls, moderately unbalanced with 2000 cases and 18000 controls, and extremely unbalanced with 40 cases and 19960 controls. For each choice of case-control ratios, the phenotypes were simulated based on the following logistic model,
where the two non-genetic covariates 1i
 is chosen to correspond to prevalence 0.01. The genotype i G s were generated from a (2, ) Binomial p distribution where p was the minor allele frequency (MAF).
The parameter  represents the genotype log odds-ratio.
To estimate computation times and type I error rates in realistic scenarios, the MAF (p) was randomly sampled from the MAF distribution in the MGI data. For the computation time comparisons, we simulated 4 10 variants with 0   . For the type I error comparisons, we simulated 9 10 variants with 0   and recorded the number of rejections at . We also used fixed MAFs to evaluate the effect of MAFs to computation time and type I error rates. For the power calculations, we considered two different choices for MAF, p = 0.01 and 0.05, and wide ranges of  (Figure 4) . For each choice of p and  we generated 5000 variants.
We compared the computation times of seven different tests: traditional score test using normal approximation (Score); the saddlepoint approximation based test with the standard deviation threshold at 0.1 and 2 (SPA-0.1 and SPA-2); the fast saddlepoint approximation based test with the partially normal approximation improvement and the standard deviation threshold at 0.1 and 2 (fastSPA-0.1 and fastSPA-2); the fastSPA test with the Berry-Esseen bound threshold at level 
Michigan Genomics Initiative (MGI) data application
To illustrate the performance of the proposed methods in real data application, we analyzed four selected phenotypes in the MGI data. The main goal of MGI is to create an institutional repository of genetic data together with rich clinical phenotypes for a broad portfolio of future medical research. 
Results
Numerical Simulations
We examine the computation time, type I error control and power of the proposed fastSPA and two existing approaches, score and Firth tests, across ranges of case-control imbalance and MAFs.
Comparison of computation times:
The projected computation times for testing 1500 phenotypes across 10 million variants using different testing methods are presented in Figure 1 . We also recorded the computation times for variants with three different fixed MAFs 0.1, 0.01 and 0.001 in order to assess the effect of MAF on the performance of the tests. Similar to Figure 1 , Table   1 also shows the superior performance of fastSPA-2 compared to all other tests. Moreover, while the computation time of SPA increases with decreasing MAFs, which may be due to the slow convergence caused by the discrete nature of the underlying distribution, fastSPA requires less computation time for rarer variants (smaller MAFs) compared to more common variants (larger MAFs). This demonstrates the potential of the partially normal approximation improvement in terms of faster computation of the p-values, especially for low-frequency and rare variants.
Type I error comparison:
The type I error rates from 10 9 simulated datasets are presented in Figure   2 . Due to the heavy computation burden for testing these extremely large numbers of datasets, in this comparison, we only considered the traditional score test, fastSPA-2, and the hybrid version of the Firth test, in which we used the Firth test only when the fastSPA-2 p-values were smaller than 3 5 10   . We note that both fastSPA-2 and Firth tests had well calibrated QQ plots up to 6 10  pvalues ( Figure 5) , and whenever fastSPA-2 p-values > ). Interestingly, it shows slight inflation ( ) in the extremely unbalanced scenario. We also estimated empirical type I error rates at six different MAFs (Figure 3) .
The score test had deflated type I error rates for low-frequency and rare variants for the balanced case-control ratio and inflated and extremely inflated type I error rates for moderately and severely unbalanced case-control ratios. The fastSPA-2 method had overall well controlled type I error rates regardless of MAFs and case-control ratios. The Firth test had either well controlled or slightly conservative type I error rates when the case-control ratio was balanced or moderately unbalanced.
However, when the case control ratio was extremely unbalanced, the Firth test had inflated type I error rates especially when the minor allele count was small (eg. Power comparison: Next, we compared the power curves of fastSPA-2, score and Firth tests. Note that the Firth test is a current gold standard method. 13 Since the traditional score test had greatly inflated type I error rates, we compared the empirical powers of different tests at their test-specific empirical  levels. Figure 4 shows power by odds ratios when the MAF of the variant was 0.05 (top panel) and 0.01 (bottom panel). As expected, the power is higher when the case-control ratio is balanced. The empirical powers of fastSPA-2 and the Firth test were nearly identical for all casecontrol ratios and MAFs, which suggests that our proposed test does not suffer from any loss in power compared to the Firth test. The empirical powers of the score test were almost identical to those of fastSPA-2 and Firth test for the balanced case-control ratio. However, the score test showed substantially low power than the other two tests for the unbalanced case-control ratios due to the very small empirical  levels, and the power gap is especially large when the case-control ratio is extremely unbalanced. The simulation results clearly show that the proposed approach improves power over the score test when type I error rates were properly controlled. When we used nominal level instead of the empirical  levels, score test had higher power than the other two approaches as expected ( Figure S3) , since its type I error rates were not controlled.
P-value and inflation factor (λ) comparison:
To compare p-value distributions of various tests, we generated QQ plots and calculated the inflation factor (λ) of the genomic control. Figure 5 suggests strong deflation (smaller than expected) in the p-values based on the traditional score test in the moderately unbalanced and extremely unbalanced case-control setups, whereas fastSPA-2, SPA-2 and Firth tests resulted in well calibrated QQ plots, which suggest that these methods can control for type I errors. Moreover, the minimum Firth p-value was None of fastSPA-2, fastSPA-BE and fastSPA-0.1 tests showed any inflation or deflation in genomic controls (λ) in the balanced and moderately unbalanced case-control setups ( Table S1 ). In the extremely unbalanced case-control setup, fastSPA-2 resulted in greatly deflated inflation factor (λ = 0.48) at the median of p-value (q = 0.5). Interestingly fastSPA-BE and fastSPA-0.1 resulted in inflated λ (both having λ = 1.83) at q = 0.5, which may be due to the discrete nature of p-values. When λ was measured at p-value quantiles q = 0.01 and 0.001, however, all three tests provided λ very close to unity.
MGI Data Analysis
We applied the traditional score test, Firth test and the fastSPA-2 method to the MGI data with four phenotypes, Skin Cancer, Type-2 diabetes, Primary Hypercoagulable state, and Cystic Fibrosis, which were selected based on case-control ratios. Skin Cancer (2359 cases, 15265 controls) and Type-2 diabetes (1987 cases, 14906 controls) were moderately unbalanced, whereas Primary
Hypercoagulable state (168 cases, 16401 controls) and Cystic Fibrosis (28 cases, 18212 controls)
were extremely unbalanced phenotypes.
The Manhattan plots ( Figure 6) show that the traditional score test produced a large number of potentially spurious associations for all of these phenotypes, whereas all of the significant variants from our proposed test at the genome-wide significant level of and all of these four genes were previously identified as associated with pigmentation traits and skin cancers. [34] [35] [36] [37] [38] [39] In the other traits, variants in TCF7L2 (MIM: 602228), F5 (MIM: 612309) and CFTR (MIM: 602421) were significantly associated with Type2 diabetes, 40 Primary Hypercoagulable State 41 and Cystic Fibrosis, 42 respectively, and all of these genes are well known to be associated with the risk of each disease. The QQ plots (Figure 7) also suggest that the p-values based on the traditional score test are much smaller than expected, especially for low-frequency and rare variants, whereas the p-values based on fastSPA-2 closely follow the uniform distribution. We also observed the Manhattan plots ( Figure S4) including the imputed variants with MAF < 0.001 in the analysis. The inclusion of rarer variants resulted in extreme inflation in the number of potentially spurious associations for the traditional score test.
However, our proposed test still produced none to very few new associations. The Manhattan plots and QQ plots for the Firth test were almost identical to those of our proposed test.
Further, based on the p-values from our proposed test, we obtained the inflation factor λ of the genomic control at different p-value quantiles (q) and different MAF cut-offs (Table S2 ). Only the imputed variants were removed when we used different MAF cutoffs. The SNPs present on the Illumina HumanCoreExome v12.1 array were preserved. To evaluate whether using a smaller standard deviation threshold (r) improves the estimation of λ, we also applied fastSPA with r = 0.1 (i.e fastSPA-0.1), and fastSPA with the Berry-Esseen bound threshold at level 
Discussion
In this paper, we proposed a fast and scalable test to analyze large PheWAS datasets which is well calibrated even in extremely unbalanced case-control settings. The method uses computationally efficient saddle point approximation to accurately calculate p-values of score test statistics. We further proposed an improved version of our test which substantially reduces the computation time, especially for low-frequency and rare variants. Our proposed test can also adjust for additional covariates. Through extensive numerical studies we demonstrated that our test can perform 100-300 times faster than the currently used Firth's test while retaining similar power and well controlled type I error rates. MGI data analysis illustrates that by applying the proposed method to PheWAS, we can identify true association signals while controlling for type I error, even for traits with a very small number of cases and a large number of controls.
Our test calculates p-values based on the traditional score test if the score statistics lie sufficiently close to the mean. Even though normal approximation is accurate near the mean, those p-values may not be well calibrated. In such cases, since the median p-values might come from the traditional score test, we can encounter slightly inflated or deflated inflation factor at median. When the case control ratio is extremely unbalanced, this phenomenon is more pronounced. One way to circumvent this issue is to measure the inflation factor at more extreme quantiles (0.01, 0.001 etc.), or to exclude rare variants when estimating the inflation factor. Another approach is to decrease the standard deviation threshold so that the median p-values come from the saddlepoint approximation.
In the MGI data analysis, fastSPA-0.1 produced substantially improved inflation factor estimates than fastSPA-2. However, the use of threshold 0.1 instead of 2 would increase computation time ~3-4x . The Berry-Esseen threshold can be viewed as a compromise between these two thresholds. If there is no restriction in computational resource, we recommend to use fastSPA-0.1 so that most of the pvalues are calculated using the saddlepoint approximation. If computational resource is limited, or researchers want to obtain results quickly, either a larger threshold (i.e fastSPA-2) or Berry-Esseen bound can be a better choice.
As sequencing cost continue to drop, whole-exome or whole-genome sequencing will be used for PheWAS to identify rare variants associated with clinical phenotypes. 31 In rare variant association analysis, gene or region based multiple variant tests are commonly used to improve power. 32 When case-control ratios are unbalanced, popular rare variant tests, including burden tests, SKAT and SKAT-O, can also have substantially inflated type I error rates. Although resampling based approaches have been developed to address this problem, 33 the existing methods are not fast enough to be used in PheWAS. One possible approach is first to adjust single variant score statistics using SPA and then to use the adjusted score statistics to control for the type I error. We left it for future research.
In summary, we have proposed an accurate and scalable method for PheWAS data analysis. With the growing effort to build large research cohorts for precision medicine 31 , future PheWAS would have hundreds of thousands of samples and hundreds of millions of variants. Our method will provide a scalable solution for this large-scale problem and contribute to finding genetic component of complex traits. All our tests are implemented in the R package SPAtest.
Supplemental Data
Four additional figures and two additional tables that were referred to in this paper, are provided in the supplemental data. 
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